Molecular Genetics of Cystic Fibrosis View Homepage


Ontology type: schema:MonetaryGrant     


Grant Info

YEARS

1991-2022

FUNDING AMOUNT

3472529 USD

ABSTRACT

Cystic fibrosis (CF) is one of the most common life-limiting autosomal recessive single gene disorders. Individuals with CF carry loss of function variants in each CF Transmembrane conductance Regulator (CFTR) gene. CFTR encodes a cAMP-activated chloride channel that ensures proper hydration and ion content of mucous secretions in the pulmonary airways and pancreatic ducts and maintains the correct concentration of chloride in sweat. Treatment of CF has taken a major step forward with the development of two classes of CFTR-targeted drugs. Ivacaftor (VX-770), a compound that potentiates the function of 33 variant forms of CFTR that are folded but inactive, has shown dramatic and lasting clinical effect. Lumacaftor (VX-809), a corrector compound, improves the folding of CFTR and demonstrates modest clinical efficacy in individuals with CF carrying the common disease-causing variant F508del. The success of these drugs indicate that we should be able to treat the vast majority of individuals with CF by targeting one or both of their CFTR variants. Several developments indicate that this goal is within reach. First, with near complete ascertainment of affected individuals by the CFTR2 project, we know that 520 variants account for 98.2% of CF alleles while the rest are `private', being reported in only one or two individuals worldwide. Second, in a major shift in policy, the Food and Drug Administration recently allowed expansion of the use of the CFTR-targeted drugs based on results of testing CFTR mutants expressed heterologously in immortalized cells. Third, we have developed and optimized a human airway cell line devoid of endogenous CFTR (termed CF8) for the functional assessment and drug response of heterologously expressed mutant forms of CFTR in a near native context. The overall goal of this application is to inform precision treatment by annotating every CF allele according to mechanism of effect, disease-liability and response to targeted drugs. This goal will be achieved by: 1) Determining disease mechanism, clinical consequences and drug response of CFTR variants to achieve annotation of 98.2% of all CF alleles reported to CFTR2; 2) Ensuring that the correct disease mechanism has been elucidated for missense variants that may also affect mRNA splicing or occur in cis with other potentially deleterious variants and 3) developing and testing predictive methods to determine disease liability and drug response of ~435 private missense variants in CFTR2. Upon completion of these aims, we estimate that 67,500 of the 70,000 individuals with CF worldwide will have mechanistic, clinical and drug response information for each CFTR variant they carry, 2,474 will have the same information for one variant leaving only 23 individuals with no information about either CFTR variant they carry. These data will be shared with the medical community and public on the CFTR2.org website. Our efforts to generate and test predictive approaches to variant annotation and drug response will provide information for rare and private CFTR variants that should inform similar efforts for all single gene disorders. More... »

URL

http://projectreporter.nih.gov/project_info_description.cfm?aid=9523485

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/2211", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }
    ], 
    "amount": {
      "currency": "USD", 
      "type": "MonetaryAmount", 
      "value": "3472529"
    }, 
    "description": "Cystic fibrosis (CF) is one of the most common life-limiting autosomal recessive single gene disorders. Individuals with CF carry loss of function variants in each CF Transmembrane conductance Regulator (CFTR) gene. CFTR encodes a cAMP-activated chloride channel that ensures proper hydration and ion content of mucous secretions in the pulmonary airways and pancreatic ducts and maintains the correct concentration of chloride in sweat. Treatment of CF has taken a major step forward with the development of two classes of CFTR-targeted drugs. Ivacaftor (VX-770), a compound that potentiates the function of 33 variant forms of CFTR that are folded but inactive, has shown dramatic and lasting clinical effect. Lumacaftor (VX-809), a corrector compound, improves the folding of CFTR and demonstrates modest clinical efficacy in individuals with CF carrying the common disease-causing variant F508del. The success of these drugs indicate that we should be able to treat the vast majority of individuals with CF by targeting one or both of their CFTR variants. Several developments indicate that this goal is within reach. First, with near complete ascertainment of affected individuals by the CFTR2 project, we know that 520 variants account for 98.2% of CF alleles while the rest are `private', being reported in only one or two individuals worldwide. Second, in a major shift in policy, the Food and Drug Administration recently allowed expansion of the use of the CFTR-targeted drugs based on results of testing CFTR mutants expressed heterologously in immortalized cells. Third, we have developed and optimized a human airway cell line devoid of endogenous CFTR (termed CF8) for the functional assessment and drug response of heterologously expressed mutant forms of CFTR in a near native context. The overall goal of this application is to inform precision treatment by annotating every CF allele according to mechanism of effect, disease-liability and response to targeted drugs. This goal will be achieved by: 1) Determining disease mechanism, clinical consequences and drug response of CFTR variants to achieve annotation of 98.2% of all CF alleles reported to CFTR2; 2) Ensuring that the correct disease mechanism has been elucidated for missense variants that may also affect mRNA splicing or occur in cis with other potentially deleterious variants and 3) developing and testing predictive methods to determine disease liability and drug response of ~435 private missense variants in CFTR2. Upon completion of these aims, we estimate that 67,500 of the 70,000 individuals with CF worldwide will have mechanistic, clinical and drug response information for each CFTR variant they carry, 2,474 will have the same information for one variant leaving only 23 individuals with no information about either CFTR variant they carry. These data will be shared with the medical community and public on the CFTR2.org website. Our efforts to generate and test predictive approaches to variant annotation and drug response will provide information for rare and private CFTR variants that should inform similar efforts for all single gene disorders.", 
    "endDate": "2022-04-30T00:00:00Z", 
    "funder": {
      "id": "https://www.grid.ac/institutes/grid.419635.c", 
      "type": "Organization"
    }, 
    "id": "sg:grant.2494517", 
    "identifier": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "2494517"
        ]
      }, 
      {
        "name": "nih_id", 
        "type": "PropertyValue", 
        "value": [
          "R01DK044003"
        ]
      }
    ], 
    "inLanguage": [
      "en"
    ], 
    "keywords": [
      "rest", 
      "CFTR2", 
      "human airway cell line", 
      "lasting clinical effect", 
      "Drug Administration", 
      "predictive approach", 
      "predictive methods", 
      "expansion", 
      "drug response", 
      "corrector compounds", 
      "efforts", 
      "chloride channels", 
      "application", 
      "results", 
      "similar efforts", 
      "clinical consequences", 
      "private missense variants", 
      "use", 
      "function variants", 
      "drug response information", 
      "variants", 
      "missense variants", 
      "goal", 
      "Molecular Genetics", 
      "proper hydration", 
      "CFTR variants", 
      "correct disease mechanism", 
      "cis", 
      "overall goal", 
      "correct concentration", 
      "ivacaftor", 
      "CF alleles", 
      "VX-770", 
      "autosomal recessive single gene disorders", 
      "CFTR2 project", 
      "common life", 
      "major step", 
      "individuals", 
      "genes", 
      "success", 
      "common disease", 
      "VX-809", 
      "mechanism", 
      "pulmonary airways", 
      "pancreatic duct", 
      "reach", 
      "lumacaftor", 
      "drugs", 
      "ion content", 
      "cystic fibrosis", 
      "CFTR mutants", 
      "cells", 
      "completion", 
      "CF8", 
      "sweat", 
      "vast majority", 
      "major shift", 
      "deleterious variants", 
      "loss", 
      "compounds", 
      "annotation", 
      "near complete ascertainment", 
      "endogenous CFTR", 
      "mutant forms", 
      "class", 
      "aim", 
      "development", 
      "function", 
      "information", 
      "cAMP", 
      "effect", 
      "variant form", 
      "CF transmembrane conductance regulator", 
      "single gene disorders", 
      "data", 
      "disease-liability", 
      "near native context", 
      "precision treatment", 
      "mucous secretion", 
      "medical community", 
      "functional assessment", 
      "food", 
      "disease mechanisms", 
      "chloride", 
      "folding", 
      "several developments", 
      "variant F508del", 
      "CFTR2.org website", 
      "response", 
      "disease liability", 
      "treatment", 
      "private CFTR variants", 
      "same information", 
      "mRNA splicing", 
      "policy", 
      "modest clinical efficacy"
    ], 
    "name": "Molecular Genetics of Cystic Fibrosis", 
    "recipient": [
      {
        "id": "https://www.grid.ac/institutes/grid.21107.35", 
        "type": "Organization"
      }, 
      {
        "affiliation": {
          "id": "https://www.grid.ac/institutes/grid.21107.35", 
          "name": "JOHNS HOPKINS UNIVERSITY", 
          "type": "Organization"
        }, 
        "familyName": "CUTTING", 
        "givenName": "GARRY R", 
        "id": "sg:person.0752157206.07", 
        "type": "Person"
      }, 
      {
        "member": "sg:person.0752157206.07", 
        "roleName": "PI", 
        "type": "Role"
      }
    ], 
    "sameAs": [
      "https://app.dimensions.ai/details/grant/grant.2494517"
    ], 
    "sdDataset": "grants", 
    "sdDatePublished": "2021-01-20T03:08", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com.uberresearch.data.processor/core_data/20181219_192338/projects/base/nih_projects_8.xml.gz", 
    "startDate": "1991-05-01T00:00:00Z", 
    "type": "MonetaryGrant", 
    "url": "http://projectreporter.nih.gov/project_info_description.cfm?aid=9523485"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/grant.2494517'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/grant.2494517'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/grant.2494517'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/grant.2494517'


 

This table displays all metadata directly associated to this object as RDF triples.

140 TRIPLES      19 PREDICATES      118 URIs      110 LITERALS      5 BLANK NODES

Subject Predicate Object
1 sg:grant.2494517 schema:about anzsrc-for:2211
2 schema:amount Nc46ad72698ca49edb628dea9a17fa1dc
3 schema:description Cystic fibrosis (CF) is one of the most common life-limiting autosomal recessive single gene disorders. Individuals with CF carry loss of function variants in each CF Transmembrane conductance Regulator (CFTR) gene. CFTR encodes a cAMP-activated chloride channel that ensures proper hydration and ion content of mucous secretions in the pulmonary airways and pancreatic ducts and maintains the correct concentration of chloride in sweat. Treatment of CF has taken a major step forward with the development of two classes of CFTR-targeted drugs. Ivacaftor (VX-770), a compound that potentiates the function of 33 variant forms of CFTR that are folded but inactive, has shown dramatic and lasting clinical effect. Lumacaftor (VX-809), a corrector compound, improves the folding of CFTR and demonstrates modest clinical efficacy in individuals with CF carrying the common disease-causing variant F508del. The success of these drugs indicate that we should be able to treat the vast majority of individuals with CF by targeting one or both of their CFTR variants. Several developments indicate that this goal is within reach. First, with near complete ascertainment of affected individuals by the CFTR2 project, we know that 520 variants account for 98.2% of CF alleles while the rest are `private', being reported in only one or two individuals worldwide. Second, in a major shift in policy, the Food and Drug Administration recently allowed expansion of the use of the CFTR-targeted drugs based on results of testing CFTR mutants expressed heterologously in immortalized cells. Third, we have developed and optimized a human airway cell line devoid of endogenous CFTR (termed CF8) for the functional assessment and drug response of heterologously expressed mutant forms of CFTR in a near native context. The overall goal of this application is to inform precision treatment by annotating every CF allele according to mechanism of effect, disease-liability and response to targeted drugs. This goal will be achieved by: 1) Determining disease mechanism, clinical consequences and drug response of CFTR variants to achieve annotation of 98.2% of all CF alleles reported to CFTR2; 2) Ensuring that the correct disease mechanism has been elucidated for missense variants that may also affect mRNA splicing or occur in cis with other potentially deleterious variants and 3) developing and testing predictive methods to determine disease liability and drug response of ~435 private missense variants in CFTR2. Upon completion of these aims, we estimate that 67,500 of the 70,000 individuals with CF worldwide will have mechanistic, clinical and drug response information for each CFTR variant they carry, 2,474 will have the same information for one variant leaving only 23 individuals with no information about either CFTR variant they carry. These data will be shared with the medical community and public on the CFTR2.org website. Our efforts to generate and test predictive approaches to variant annotation and drug response will provide information for rare and private CFTR variants that should inform similar efforts for all single gene disorders.
4 schema:endDate 2022-04-30T00:00:00Z
5 schema:funder https://www.grid.ac/institutes/grid.419635.c
6 schema:identifier N9b0bb1eb7a484c9a9e18f8a38c0a5cf5
7 Nad2b7cd1812343f085828bfe88b4fdaf
8 schema:inLanguage en
9 schema:keywords CF alleles
10 CF transmembrane conductance regulator
11 CF8
12 CFTR mutants
13 CFTR variants
14 CFTR2
15 CFTR2 project
16 CFTR2.org website
17 Drug Administration
18 Molecular Genetics
19 VX-770
20 VX-809
21 aim
22 annotation
23 application
24 autosomal recessive single gene disorders
25 cAMP
26 cells
27 chloride
28 chloride channels
29 cis
30 class
31 clinical consequences
32 common disease
33 common life
34 completion
35 compounds
36 correct concentration
37 correct disease mechanism
38 corrector compounds
39 cystic fibrosis
40 data
41 deleterious variants
42 development
43 disease liability
44 disease mechanisms
45 disease-liability
46 drug response
47 drug response information
48 drugs
49 effect
50 efforts
51 endogenous CFTR
52 expansion
53 folding
54 food
55 function
56 function variants
57 functional assessment
58 genes
59 goal
60 human airway cell line
61 individuals
62 information
63 ion content
64 ivacaftor
65 lasting clinical effect
66 loss
67 lumacaftor
68 mRNA splicing
69 major shift
70 major step
71 mechanism
72 medical community
73 missense variants
74 modest clinical efficacy
75 mucous secretion
76 mutant forms
77 near complete ascertainment
78 near native context
79 overall goal
80 pancreatic duct
81 policy
82 precision treatment
83 predictive approach
84 predictive methods
85 private CFTR variants
86 private missense variants
87 proper hydration
88 pulmonary airways
89 reach
90 response
91 rest
92 results
93 same information
94 several developments
95 similar efforts
96 single gene disorders
97 success
98 sweat
99 treatment
100 use
101 variant F508del
102 variant form
103 variants
104 vast majority
105 schema:name Molecular Genetics of Cystic Fibrosis
106 schema:recipient N402cc7fada174648bce34cc5cd376014
107 sg:person.0752157206.07
108 https://www.grid.ac/institutes/grid.21107.35
109 schema:sameAs https://app.dimensions.ai/details/grant/grant.2494517
110 schema:sdDatePublished 2021-01-20T03:08
111 schema:sdLicense https://scigraph.springernature.com/explorer/license/
112 schema:sdPublisher Nfb430a98d8c74ecd8848f3e993b199fb
113 schema:startDate 1991-05-01T00:00:00Z
114 schema:url http://projectreporter.nih.gov/project_info_description.cfm?aid=9523485
115 sgo:license sg:explorer/license/
116 sgo:sdDataset grants
117 rdf:type schema:MonetaryGrant
118 N402cc7fada174648bce34cc5cd376014 schema:member sg:person.0752157206.07
119 schema:roleName PI
120 rdf:type schema:Role
121 N9b0bb1eb7a484c9a9e18f8a38c0a5cf5 schema:name nih_id
122 schema:value R01DK044003
123 rdf:type schema:PropertyValue
124 Nad2b7cd1812343f085828bfe88b4fdaf schema:name dimensions_id
125 schema:value 2494517
126 rdf:type schema:PropertyValue
127 Nc46ad72698ca49edb628dea9a17fa1dc schema:currency USD
128 schema:value 3472529
129 rdf:type schema:MonetaryAmount
130 Nfb430a98d8c74ecd8848f3e993b199fb schema:name Springer Nature - SN SciGraph project
131 rdf:type schema:Organization
132 anzsrc-for:2211 schema:inDefinedTermSet anzsrc-for:
133 rdf:type schema:DefinedTerm
134 sg:person.0752157206.07 schema:affiliation https://www.grid.ac/institutes/grid.21107.35
135 schema:familyName CUTTING
136 schema:givenName GARRY R
137 rdf:type schema:Person
138 https://www.grid.ac/institutes/grid.21107.35 schema:name JOHNS HOPKINS UNIVERSITY
139 rdf:type schema:Organization
140 https://www.grid.ac/institutes/grid.419635.c schema:Organization
 




Preview window. Press ESC to close (or click here)


...